Antiemetic Drugs Requiring Only Once-Daily Administration Due to Longer Half-Life

Introduction to Palonosetron

• The American Society of Clinical Oncology recommends palonosetron as the primary antiemetic that should be administered only once due to its significantly longer half-life of approximately 40 hours, compared to other 5-HT3 receptor antagonists 1, 2

Palonosetron Pharmacology

• Palonosetron has a half-life of approximately 40 hours, which is at least 4 times longer than any other available 5-HT3 receptor antagonist 1, 2
• Palonosetron has a binding affinity approximately 100-fold higher for the 5-HT3 receptor compared to first-generation agents (ondansetron, granisetron, dolasetron) 1, 2

Dosing Specifications

• For moderately emetogenic chemotherapy, a single dose of 0.25 mg IV or 0.50 mg oral palonosetron on day 1 is sufficient, with no additional doses required on subsequent days 3, 4
• For highly emetogenic chemotherapy, a single dose of 0.25 mg IV palonosetron on day 1 is sufficient, with no additional doses required on subsequent days 3, 4

Alternative Long-Acting Formulations

• Granisetron extended-release formulations, such as a transdermal patch, allow for less frequent dosing, with a 3.1 mg/24-hour patch applied every 7 days 5, 6
• A subcutaneous extended-release injection of granisetron delivers therapy over multiple days, but is not interchangeable with IV formulations and should not be administered at intervals less than one week 3, 4, 7

Combination Products with Extended Coverage

• Netupitant-palonosetron and fosnetupitant-palonosetron combinations provide single-dose administration on day 1, with coverage without need for additional 5-HT3 antagonist 3, 4
• Netupitant-palonosetron is administered as 300 mg netupitant/0.5 mg palonosetron oral in a single capsule, while fosnetupitant-palonosetron is administered as 235 mg fosnetupitant/0.25 mg palonosetron IV 3, 4

Clinical Superiority of Palonosetron

• Palonosetron demonstrates superior efficacy compared to first-generation agents, particularly for delayed emesis, with response rates of 81% vs 69% for acute emesis and 74% vs 55% for delayed emesis in moderately emetogenic chemotherapy 1, 2
• Palonosetron is more effective than ondansetron for delayed emesis in highly emetogenic chemotherapy when combined with dexamethasone, with response rates of 41% vs 25% 1, 2

Special Consideration for Multi-Day Chemotherapy

• For multi-day chemotherapy regimens, palonosetron may be used as a single dose before the start of a 3-day chemotherapy regimen instead of multiple daily doses of other 5-HT3 antagonists 8
• The need for repeat dosing with palonosetron in multi-day chemotherapy settings is not yet fully defined, but some studies suggest repeat dosing on days 1, 3, and 5 for highly emetogenic multi-day regimens 8